Highly transmissible Omicron variants of SARS-CoV-2 currently dominate globally. Here, we
compare neutralization of Omicron BA. 1, BA. 1.1, and BA. 2. BA. 2 RBD has slightly higher …

Neutralizing antibodies can block infection, clear pathogens, and are essential to provide
long-term immunity. Since the onset of the pandemic, SARS-CoV-2 neutralizing antibodies …

SARS-CoV-2 Omicron variant has presented significant challenges to current antibodies
and vaccines. Herein, we systematically compared the efficacy of 50 human monoclonal …

A severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron subvariant, BA.
2.86, has emerged and spread to numerous countries worldwide, raising alarm because its …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused the global
COVID-19 pandemic infecting more than 106 million people and causing 2.3 million deaths …

Neutralizing antibodies (nAbs) elicited against the receptor binding site (RBS) of the spike
protein of wild-type severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are …

An ideal therapeutic anti-SARS-CoV-2 antibody would resist viral escape,–, have activity
against diverse sarbecoviruses,,–, and be highly protective through viral neutralization,,–and …

SARS-CoV-2 is a betacoronavirus virus responsible for the COVID-19 pandemic. Here, we
determine the X-ray crystal structure of a potent neutralizing monoclonal antibody, CV30 …

Antibodies elicited by infection accumulate somatic mutations in germinal centers that can
increase affinity for cognate antigens. We analyzed 6 independent groups of clonally related …

Antibodies that potently neutralize SARS-CoV-2 target mainly the receptor-binding domain
or the N-terminal domain (NTD). Over a dozen potently neutralizing NTD-directed antibodies …